ArticleInternal medicine (Tokyo, Japan)2025
Successful Reswitching of Thrombopoietin Receptor Agonists: Two Cases of Immune Thrombocytopenia and Severe Aplastic Anemia.
Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Eltrombopag Combined With Cyclosporine A in the Treatment of Pediatric Patients With SAA: Establishing the Range for Eltrombopag Concentrations.Clinical and translational science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We used thrombopoietin receptor agonists (TPO-RAs) to treat immune thrombocytopenia (ITP) and aplastic anemia (AA). Molecular structures and methods of action differ among TPO-RAs; therefore, switching to another may be beneficial if one fails. In elderly people, planning and attending outpatient visits may complicate weekly subcutaneous romiplostim delivery. In two cases, the patient was initially unresponsive to eltrombopag, so we switched to romiplostim and then switched back due to hospital visits, which resulted in stabilizing platelet counts. We suggest better management techniques for patients, as ITP and AA require long-term management, which becomes increasingly challenging with increasing patient age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.